Down 33% intraday: 1H3.SI stock S$0.002 on SES, liquidity risk rises

Today (03 Feb 2026) Clearbridge Health Limited (1H3.SI) plunged -33.33% intraday to S$0.002 on the Singapore Exchange (SES), marking it as one of the session’s top losers. The move came on 824,200 shares traded versus an average volume of 9,625,614, raising short-term liquidity concerns for retail and institutional traders. This article examines why the 1H3.SI stock fell, the company’s valuation and technicals, and what Meyka AI’s model and our analysis imply for near-term price action.

Intraday drop: 1H3.SI stock move

The intraday decline in 1H3.SI stock to S$0.002 represents a -33.33% fall from the previous close of S$0.003, with the share price trading between S$0.002 and S$0.002 today on SES.

Drivers of the sell-off and news context

There is no fresh earnings release today, but the stock shows fragile trading history and an upcoming earnings announcement scheduled for 2026-02-27, which may prompt positioning ahead of results; the company website lists operations across Singapore, the Philippines and Malaysia and offers imaging and clinic services source.

Fundamentals and valuation snapshot for 1H3.SI stock

Clearbridge Health has market capitalisation of S$8,591,642, price-to-sales 1.16, price-to-book 0.27, negative PE (TTM) at -1.53, and book value per share 0.0085, highlighting weak profitability but low book-based valuation versus peers in the Healthcare sector.

Technicals and liquidity: what traders see

Trading volume today was 824,200, below the 50-day average of 9,625,614, yet relative volume is elevated at 2.46, RSI sits near 51.74, and ADX shows a strong trend at 66.13, signalling directional selling with limited liquidity in an already thin market.

Meyka Grade & Meyka AI’s forecast for 1H3.SI stock

Meyka AI rates 1H3.SI with a score of 57.64 out of 100 (Grade: C+, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of S$0.009 versus the current S$0.002, implying approximately 350.00% upside; forecasts are model-based projections and not guarantees.

Analyst signals, risks and sector positioning

Independent company ratings show a C score with a Sell recommendation dated 2026-02-02; major risks include thin liquidity, negative net income per share -0.00130, negative operating cash flow per share -0.00070, and exposure to discretionary healthcare spending across Southeast Asia, while the Healthcare sector is up modestly year-to-date versus this stock’s decline.

Final Thoughts

Clearbridge Health (1H3.SI) is the session’s clear top loser on SES, down -33.33% intraday to S$0.002 on 03 Feb 2026. The move reflects thin liquidity, a stretched float and weak trailing profitability with PE (TTM) at -1.53 and negative net income per share -0.00130. Meyka AI’s grade of 57.64/100 (C+, HOLD) balances low valuation (PB 0.27) against poor cash conversion and negative margins. Our model-based outlook uses Meyka AI’s forecast of S$0.009 in one year, implying roughly 350.00% upside versus current levels, but this projection comes with high uncertainty given low market depth and upcoming earnings on 2026-02-27. Active traders should prioritise liquidity and position size; longer-term investors should wait for improved cash flows or clearer operational signals before adding exposure to 1H3.SI stock. Meyka AI provides this AI-powered market analysis platform insight but this is not financial advice and forecasts are not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.